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Genomic approaches in the search 
for molecular biomarkers in chronic kidney 
disease
M. Cañadas‑Garre1* , K. Anderson1, J. McGoldrick1, A. P. Maxwell1,2 and A. J. McKnight1
Abstract 
Background: Chronic kidney disease (CKD) is recognised as a global public health problem, more prevalent in older 
persons and associated with multiple co‑morbidities. Diabetes mellitus and hypertension are common aetiologies for 
CKD, but IgA glomerulonephritis, membranous glomerulonephritis, lupus nephritis and autosomal dominant polycys‑
tic kidney disease are also common causes of CKD.
Main body: Conventional biomarkers for CKD involving the use of estimated glomerular filtration rate (eGFR) derived 
from four variables (serum creatinine, age, gender and ethnicity) are recommended by clinical guidelines for the 
evaluation, classification, and stratification of CKD. However, these clinical biomarkers present some limitations, espe‑
cially for early stages of CKD, elderly individuals, extreme body mass index values (serum creatinine), or are influenced 
by inflammation, steroid treatment and thyroid dysfunction (serum cystatin C). There is therefore a need to identify 
additional non‑invasive biomarkers that are useful in clinical practice to help improve CKD diagnosis, inform prognosis 
and guide therapeutic management.
Conclusion: CKD is a multifactorial disease with associated genetic and environmental risk factors. Hence, many 
studies have employed genetic, epigenetic and transcriptomic approaches to identify biomarkers for kidney disease. 
In this review, we have summarised the most important studies in humans investigating genomic biomarkers for CKD 
in the last decade. Several genes, including UMOD, SHROOM3 and ELMO1 have been strongly associated with renal 
diseases, and some of their traits, such as eGFR and serum creatinine. The role of epigenetic and transcriptomic bio‑
markers in CKD and related diseases is still unclear. The combination of multiple biomarkers into classifiers, including 
genomic, and/or epigenomic, may give a more complete picture of kidney diseases.
Keywords: Genomic biomarkers, Genomics, Epigenetics, Transcriptomics, Chronic kidney disease, Diabetic kidney 
disease
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Introduction
Chronic kidney disease (CKD) is recognised as a global 
public health problem [1] with adjusted CKD prevalence 
ranging between 3.3 and 17.3% in adult European popu-
lations [2]. CKD is more prevalent in older persons and 
is associated with multiple co-morbidities including an 
increased risk of cardiovascular disease (CVD). Diabetes 
mellitus (DM) and hypertension are common aetiologies 
for CKD. Other common causes of CKD include auto-
immune renal diseases such as IgA glomerulonephritis 
(IgAN), membranous glomerulonephritis (MGN) and 
lupus nephritis (LN). Autosomal dominant polycystic 
kidney disease (ADPKD) is the commonest genetic disor-
der causing CKD [3].
The 2012 Kidney Disease: Improving Global Outcomes 
(KDIGO) Clinical Practice Guideline for the Evalua-
tion and Management of CKD, developed by the Kidney 
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National Kidney Foundation (NKF), recommends the 
use of estimated glomerular filtration rate (eGFR) in the 
evaluation, classification, and stratification of CKD [3]. 
The guidelines, categorise CKD into five stages based on 
eGFR measurements (Table  1) [3, 4]. The most widely 
used eGFR equation is derived from four variables 
(serum creatinine (SCr), age, gender and ethnicity), and 
is recommended by the KDOQI guidelines for initial 
assessment of kidney function [4].
Although SCr assays are routinely available in clinical 
practice there are some limitations to its use as creati-
nine is influenced by muscle mass, exercise, age, gender, 
and ethnicity. Furthermore, ~ 50% of kidney function can 
be lost before the SCr rises above the normal laboratory 
range [5, 6]. An eGFR equation, based on SCr (eGFR-
crea), is not an accurate measure for early stages of CKD, 
in elderly individuals with low muscle mass and in those 
with extreme body mass index values [7]. A second equa-
tion, based on the measurement of serum cystatin C, 
has been proposed as an alternative [4]. The use of eGFR 
based on cystatin C (eGFRcys) is recommended by the 
KDOQI guidelines as a confirmatory test to diagnose 
CKD in those specific circumstances when eGFR-cre-
atinine is less accurate [3, 4]. However, serum cystatin C 
measurements also have recognised limitations since the 
circulating cystatin C level can be increased by inflam-
mation, steroid treatment and thyroid dysfunction [8]. 
Urinary albumin, the principal component of urinary 
protein in most kidney diseases, is also routinely used as 
a marker of kidney damage. Although albuminuria may 
be an early sign of kidney disease in glomerulonephritis 
(an can occur prior to a decrease in glomerular filtration 
rate) it is not a universal feature of CKD [3]. Repeated 
assessments, employing the existing eGFR equations 
and urinary albumin measurements, can help to identify 
persons with CKD. There is however an ongoing need to 
identify additional non-invasive biomarkers that are use-
ful in clinical practice to help improve CKD diagnosis, 
inform prognosis and guide therapeutic management.
CKD is a multifactorial disease with associated genetic 
and environmental risk factors. The increasing need to 
identify CKD patients at earlier stages and improve strat-
ification of their risk for progression to end-stage renal 
disease (ESRD) has prompted many studies of novel and 
existing biomarkers for kidney disease in large cohorts of 
patients. Various approaches have been employed, from 
candidate single gene studies to genome wide multi-omic 
studies. Among them, many genetic, epigenetic, and 
transcriptomic studies have been developed in the hope 
that the introduction of novel technologies and unbiased 
approaches would allow the identification of new bio-
markers for CKD that would also contribute to biological 
understanding of renal disease.
In this review, we will summarise the most important 
studies in humans investigating genomic biomarkers for 
CKD in the last decade.
Genetic biomarkers
A genetic susceptibility to CKD exists although there is 
limited evidence for the individual gene variants respon-
sible for this risk across the multiple aetiologies of CKD 
[9, 10]. Unlike Mendelian kidney disorders, such as 
ADPKD, where the causal variants are in the PKD1 and 
PKD2 genes [11], CKD is considered to be a polygenic 
disease in which many common, low-penetrance vari-
ants influence disease development and progression [12]. 
In the past, studies of candidate genes from pathways 
associated with renal function and linkage analysis in 
extended family pedigrees with multiple affected genera-
tions have been utilised to identify causal variants which 
contribute to CKD [13, 14]. However, both approaches 
have their drawbacks; candidate gene studies require 
knowledge of disease pathways and bias is introduced 
in gene selection, while genome-wide linkage analyses 
do not reflect genomic variation across all populations, 
as analyses are carried out within families [15]. More 
recently, genome-wide association studies (GWAS) have 
been employed to detect genetic variations in large num-
bers of unrelated individuals. For over 10  years, GWAS 
have been employed to identify single nucleotide poly-
morphisms (SNPs) associated with CKD and/or a range 
of traits associated with renal function. Serum creatinine 
(SCr), eGFR and urinary albumin-to-creatinine ratio 
(UACR), have been investigated using GWAS in differ-
ent aetiologies of CKD and ESRD, such as diabetic kid-
ney disease (DKD), MGN and IgAN. Genetic variants 
in over 50 loci have been associated with CKD or meas-
ures of renal function in different populations. Several of 
these gene variants are implicated in pathways driving 
the pathogenesis of CKD. The relevance of GWAS for 
the identification of SNPs associated with kidney trans-
plantation outcomes and their potential use as genetic 
Table 1 Categorisation of  chronic kidney disease 
according to estimated glomerular filtration rate [4]






Group 1 ≥ 90 Normal or high
Group 2 60–89 Mildly decreased
Group 3a 45–59 Mildly to moderately decreased
Group 3b 30–44 Moderately to severely decreased
Group 4 15–29 Severely decreased
Group 5 < 15 Kidney failure
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biomarkers for risk stratification or donor selection has 
been recently reviewed [16]. A small number of genetic 
variants were associated with graft function, T cell medi-
ated rejection and tacrolimus trough levels, but these 
markers have not been validated in multiple different 
populations [16].
Various genetic loci have been associated with CKD 
(Table 2), but by far the most widely reported and con-
sistently replicated genetic variants lie within the UMOD 
gene. UMOD codes for the protein uromodulin (pre-
viously known as Tamm-Horsfall [17], which is pro-
duced in the kidneys and is the most abundant urinary 
protein [18]. Loss of UMOD in mice leads to dysfunc-
tion of transmembrane solute transporters in the loop 
of Henle [19]. Mutations in UMOD have been associ-
ated with autosomal dominant tubulointerstitial kidney 
disease [20] which can progress to CKD [21]. Discovery 
analysis of 2388 CKD patients and 17,489 non-CKD con-
trols and replication analysis of 1932 CKD patients and 
19,534 controls of European ancestry, found UMOD 
variant rs12917707 to be significantly associated with 
both CKD and eGFR [22]. The same group confirmed 
these findings in a larger study in a total of 7173 Euro-
pean patients across the discovery and replication anal-
yses [23]. A meta-analysis of population-based studies 
comprising over 130,600 individuals also found signifi-
cant association with rs12917707 in 6271 cases of CKD 
(p = 3.7 × 10−16) and significant association in 2181 
patients whose CKD was more severe (eGFR < 45  ml/
min/1.73 m2; p = 1.1 × 10−05) [24]. An additional variant 
(rs4293393) in the UMOD gene was significantly associ-
ated with CKD (p = 4.1 × 10−10) in a study of 3203 Icelan-
dic CKD patients and 38,782 controls [25]. This variant 
was replicated in a larger study of 15,594 Icelandic CKD 
patients (p = 9.1 × 10−38), in which another UMOD vari-
ant (rs11864909) was found to be significantly associ-
ated with CKD in a combined analysis (p = 2.2 × 10−19). 
Another UMOD variant, rs13329952 was significantly 
associated with CKD in a fixed-effects meta-analysis on 
a total of 151,137 individuals, of which 16,630 had CKD 
(p = 1.98 × 10−25); variant rs12917707 was also replicated 
in this meta-analysis (p = 1.16 × 10−41) [26].
There are ethnic differences in the incidence and preva-
lence of CKD; the incidence of ESRD is almost five times 
higher in African Americans than Americans of Euro-
pean descent [27]. A study of 1372 African American 
ESRD patients and 806 controls identified several vari-
ants in the myosin heavy chain type II isoform A (MYH9) 
gene as being specifically associated with non-diabetic 
ESRD in African Americans [28]. To further investigate 
this association, ESRD patients were sub-divided by pres-
ence of diabetes. No association was found in diabetic 
ESRD patients, but significance of MYH9 variants was 
retained for the non-diabetic ESRD group [28]. Similar 
association was found in variants spanning exon 14–23 of 
the MYH9 gene in 852 focal segmental glomerulosclero-
sis (FSGS) and 433 non-diabetic ESRD patients, but not 
for 476 diabetic-ESRD patients when compared to 222 
controls [29]. The results for ESRD patients were consist-
ent with the first analysis, and both studies described a 
specific association between variant rs735853 and non-
diabetic ESRD patients, but not with diabetic ESRD 
patients [28, 29]. A study of 464 non-diabetic ESRD 
patients and 478 controls, replicated in 336 non-DM 
ESRD cases and 363 controls, identified 16 SNPs asso-
ciated with non-diabetic ESRD, 12 of which were found 
in/near MYH9 [30]. To reinforce the specificity of these 
variants in African American individuals, a sufficiently 
powered study in 23,812 European patients found no 
association of MYH9 with eGFR or CKD [31]. Despite the 
lack of previous association with diabetic-ESRD, two sub-
sequent studies found significant association of MYH9 
with type 2 diabetes mellitus (T2DM)-ESRD [32, 33]. The 
MYH9 gene codes for myosin non-muscle myosin heavy 
chain IIA protein [34], a protein involved in cytokinesis, 
chemotaxis and differentiation of non-muscle cells [35]. 
Mutations in this gene are responsible for a number of 
autosomal dominant conditions and patients, such as 
those with Epstein Syndrome, can develop nephritis or 
other renal abnormalities [36]. This known link to renal 
function further supports the role of MYH9 as a genomic 
biomarker in CKD, although further studies in patients of 
European descent with CKD may be required to deter-
mine its suitability a biomarker across populations or 
should be limited to African Americans.
However, strong linkage disequilibrium found among 
variants in MYH9 and the adjacent APOL1 gene made 
it unclear as to which variants were associated disease 
[37]. With the release of data from the 1000 genomes 
project, two independent groups identified variants in 
APOL1 which were associated with non-diabetic ESRD 
[38, 39]. In a study of 1030 non-diabetic ESRD patients 
and 1025 non-diabetic non-ESRD controls, two variants 
in APOL1 (rs73885319 and rs71785313, referred to as G1 
and G2, respectively) reached genome-wide significance 
(G1: p = 1.1 × 10−39, G2: p = 8.8 × 10−18) [39]. The same 
study found similar association of G1 (p = 1.07 × 10−23) 
and G2 (p = 4.38 × 10−7) with FSGS in 205 FSGS Afri-
can Americans patients and 180 non-FSGS controls [39]. 
After adjusting for G1 and G2 using logistic regression, 
association with MYH9 was lost for both non-diabetic 
ESRD and FSGS, but association with variants in APOL1 
remained when adjusting for variants in MYH9 [39]. An 
independent group was carrying out similar analysis at 
the same time in 346 African American and 84 Hispanic 
American ESRD patients and 147 African American 
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and 378 Hispanic American controls [38]. In this study 
they also found that variants in APOL1 (rs73885319 and 
rs60910145) were much more strongly associated with 
ESRD than all previously reported variants in MYH9 [38]. 
The G1 and G2 risk alleles were also found to be asso-
ciated with a greater risk of developing CKD (OR = 1.49, 
CI 1.02–2.07) and greater risk of progression to ESRD 
(OR = 1.88, CI 1.20–2.93) in 3067 African American indi-
viduals did not have CKD at baseline, of which 190 went 
on to develop CKD and 114 developed ESRD [40].
APOL1 codes for apolipoprotein L1 (APOL1), a pro-
tein which interacts with high density lipoprotein (HDL) 
cholesterol in plasma [41]. APOL1 was identified as a 
protective factor in human sleeping sickness, common in 
Sub-Saharan Africa [42], and it has been shown that only 
variants in APOL1 linked with renal dysfunction confer 
protection from disease [39]. Therefore, these variants 
may have been passed on due to their protective effect 
against human sleeping sickness in Africans, resulting 
in higher prevalence of APOL1 variants in individuals of 
African origin, compared to those of Europeans.
Other loci have shown association with CKD, such 
as PRKAG2 [23, 24, 26, 43] and WDR37 [23, 24, 26, 43], 
variants within these genes are reported less often than 
those in UMOD or MYH9/APOL1.
eGFR
Variants in the UMOD gene have demonstrated the abil-
ity not only to predict the risk of CKD, but also changes 
in eGFR. The rs12917707 variant was the first SNP in 
UMOD to reach genome-wide significance for both 
SCr eGFRcrea and eGFRcys [22]. Estimating GFR inde-
pendently of creatinine discriminates between asso-
ciation derived from renal function and from creatinine 
production or metabolism. Meta-analysis of discovery 
(n = 19,877) and replication (n = 21,466) analyses of 
independent European patient cohorts showed signifi-
cance of UMOD with eGFRcrea (p = 3.0T × 10−11) and 
eGFRcys (p = 2.0 × 10−07), showing UMOD is associ-
ated with renal function decline and not creatinine pro-
duction or metabolism [22]. The rs12917707 variant has 
been associated with SCr/eGFR in patients of European 
ancestry in several other studies, both with and with-
out diabetes [24, 44, 45]. It also showed a stronger asso-
ciation with older individuals when patient groups were 
stratified by age (p = 8.4 × 10−13) [24] and with significant 
changes in eGFR over time and kidney function decline 
in a total of 63,558 patients [45]. Another variant in 
UMOD (rs4293393) correlated with SCr in a combined 
analysis of 24,375 Icelandic and Dutch participants [25]. 
This variant was replicated for SCr in 194,286 Icelandic 
individuals (p = 2.48 × 10−38), where additional UMOD 
variants (rs11864909; p = 4.05 × 10−21) and rs12917707 
(p = 2.03 × 10−36) also reached genome-wide significance 
[43]. More recently, rs12917707 and another UMOD var-
iant (rs13329952, p = 9.47 × 10−43) were found to be sig-
nificantly associated with eGFRcrea. Variant rs12917707 
showed association both in patients with diabetes 
(n = 118,365, p = 2.48 × 10−08) and without (n = 11,522, 
p = 4.68 × 10−36) [26].
In summary, as several different UMOD SNPs have 
been linked to both CKD and eGFR, UMOD may prove 
to be useful as a diagnostic and prognostic genomic 
biomarker of CKD. Indeed, levels of serum uromodu-
lin have recently been shown to useful in disease detec-
tion as CKD patients were shown to have a significantly 
lower serum uromodulin concentration (p < 0.001) and 
measurement of serum UMOD was shown to signifi-
cantly enhance performance of a CKD prediction model 
(p = 0.049) [46]. UMOD often exhibits one of the strong-
est associations with CKD [22, 26], suggesting that 
UMOD would likely be suitable as a diagnostic genomic 
biomarker of CKD.
Multiple variants (rs17319721 [22, 24, 25, 43, 44], 
rs2137154 [43], rs9992101 [43] and rs13146355 [43] 
in SHROOM3 have also been associated with eGFR 
in patients of European ancestry [22, 24, 25, 43, 44]. 
SHROOM3 encodes the shroom3 protein, which has been 
shown to regulate cell shape by coordinating cytoskeleton 
assembly [47] and whose overexpression (due to pres-
ence of variant rs17319721) is associated with increased 
allograft fibrosis in renal transplant patients [48]. The 
SHROOM3 rs17319721 variant was first identified in 
patients within four cohorts from Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) 
consortium [22]. Meta-analysis of 19,877 patients of 
European ancestry from CHARGE, to two additional 
population-based studies (n = 21,466) were used for dis-
covery and replication, respectively [22]. After UMOD, 
the most significant genome-wide association with eGFR 
(estimated using SCr) was with SHROOM3, found in 
both discovery (p = 9.7 × 10−08) and combined discovery 
and replication meta-analyses (p = 1.2 × 10−12) [22]. The 
same variant showed association with SCr in a study of 
22,256 Icelandic patients (p =  0.00057) [25], and asso-
ciation with eGFR was observed in a combined discov-
ery and replication meta-analysis of 74,354 and 56,346 
patients of European ancestry (p = 1.5 × 10−21) [24]. In 
the same study, association of SHROOM3 (rs17319721) 
and eGFR remained significant after stratifying patients 
by age, sex, diabetes and hypertension status, but a paral-
lel investigation in patients of African ancestry yielded no 
association, highlighting the genetic differences between 
patients of different ethnic origins [24]. The rs17319721 
variant in SHROOM3 was associated with eGFR in a 
study of 3028 Caucasian patients with type 2 diabetes 
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(p = 3.18 × 10−03), showing a larger impact on baseline 
eGFR when patients presented with albuminuria [44]. 
In a study of 81,656 Icelandic patients and their 112,630 
relatives (correction made for relatedness), genome-
wide significance was reached for each variant with SCr, 
in both discovery and replication analyses (rs17319721: 
p = 4.8 × 10−10, rs2137154: p = 4.7 × 10−13, rs9992101: 
p = 1.0 × 10−10 and rs13146355: p = 6.5 × 10−12) [43].
A number of other genes have shown specific associa-
tion with eGFR, such as STC1 [23–26, 43], SLC22A2 [23, 
24, 26, 31, 43] and WDR37 [23, 24, 26, 43, 49] are thought 
to be involved in creatinine secretion, rather renal func-
tion, therefore not being representative of CKD. This 
highlights the importance of functional analysis of sig-
nificantly associated variants to determine their role in 
CKD. A second measure of eGFR, such as serum cysta-
tin-C, may need to be incorporated into future studies to 
control for variants associated with creatinine secretion.
Diabetic kidney disease
The Engulfment and Cell Motility 1 gene (ELMO1) has 
been studied extensively in DKD (Table  3). Located on 
chromosome 7, ELMO1 codes for a protein of the same 
name involved in a pathway promoting phagocytosis of 
apoptotic cells [50]. A variant in intron 18 of chromo-
some 7p14 showed significant association with DKD 
(p = 5 × 10−5) in 560 Japanese patients and 360 T2DM 
controls [51]. As DKD often leads to ESRD [52], a follow-
up study of ELMO1 gene variants in African American 
patients with T2DM-ESRD was carried out [53]. Com-
bined analyses for a total of 1135 T2DM-ESRD patients 
was performed compared to a combination of healthy 
(n = 596), non-diabetic ESRD (n = 326) and T2DM con-
trols (n = 328) in order to determine which SNPs were 
specifically associated with T2DM-ESRD and not the 
individual T2DM or ESRD traits [53]. A total of 13 vari-
ants in ELMO1 showed significant association with 
T2DM-ESRD, 11 of which were found in intron 13 [53]. 
These variants showed no association in patients with 
T2DM or ESRD singularly, indicating these SNPs are 
specific for DKD [53]. To extrapolate these findings in 
Japanese and African American patients, an additional 
study was carried out in patients of European ancestry, to 
determine if association of ELMO1 and DKD was inde-
pendent of ethnic origin. In a study of advanced DKD, 
defined as the presence of persistent proteinuria or ESRD, 
284 DKD patients with proteinuria and 536 patients with 
DKD-ESRD were analysed for association of 359,193 
SNPs, 106 in ELMO1, versus 885 type 1 diabetes melli-
tus (T1DM) controls [54, 55]. Eleven nominally signifi-
cant SNPs were identified within four novel genomic loci, 
including variants in FRMD3 (p = 5.0 × 10−7) and CARS 
(p = 3.1 × 10−6), which were also shown to contribute 
significantly to time needed to develop DKD (FRMD3, 
p = 0.02 and CARS, p = 0.01) [54].
While eight ELMO1 variants showed nominal asso-
ciation with DKD, and variant rs7785934 was found to 
be significantly associated with the ESRD group, three 
nominally associated variants (rs1558688, rs741301, and 
rs7799004) showed opposite genetic effect compared to 
the previous Japanese cohort study [54]. Ethnic differ-
ences may account for differences among studies, as a 
second, larger study in 1154 patients and 1988 controls 
of European ancestry from the GENIE consortium also 
failed to find genome-wide association between DKD 
and ELMO1, but found similar association for other 11 
“top-hits” from a previous analysis in European patients 
[56]. Although performed in an animal model, diabetic 
mice with increased expression of ELMO1 show renal 
dysfunction similar to that seen in human DKD [57]. 
When the same mutation was induced in both diabetic 
and non-diabetic mice, ELMO1 expression was almost 
twofold higher in the diabetic mice [57]. This may explain 
why ELMO1 variants are significantly associated spe-
cifically with DKD, but further functional analysis in 
humans is required.
This study by the GENIE consortium also examined 
the erythropoietin gene (EPO) promoter, previously 
found associated (variant rs1617640; p = 2.76 × 10−11) in 
a total of 1618 diabetic ESRD patients with proliferative 
diabetic retinopathy and 954 controls from three inde-
pendent North American cohorts of European American 
ancestry [58]. The EPO variant rs1617640 was not repli-
cated (although direction of effect was consistent) in the 
GENIE consortium patients, but the fixed-effects meta-
analysis of the original and replication cohorts reached 
genome-wide significance (p = 2×10−9) [56].
Other traits and kidney diseases
Albuminuria, often measured using UACR, has been 
previously associated with increased risk of progres-
sion to ESRD [59]; therefore, genetic variants associated 
with increased UACR may help predict CKD progres-
sion. A meta-analysis of 63,153 individuals of European 
ancestry from the CKDGen consortium identified asso-
ciation between variant rs1801239 in the CUBN gene 
and both UACR (p = 1.1 × 10−11) and microalbuminu-
ria (p = 0.001), defined as UACR > 25  mg/g in women 
and > 17 mg/g in men [60]. Cubilin, the protein encoded 
by CUBN, when expressed in the kidney, complexes with 
membrane transporter megalin to reabsorb urinary albu-
min [61]. Cubilin has been suggested as a biomarker for 
renal cell carcinoma but may also hold promise as a use-
ful addition to a biomarker panel for CKD [62]. As vari-
ants detected often differ among patients of different 
ethnicities, the rs1801239 variant in the CUBN gene was 
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examined in 6981 African American individuals from 
the CARe consortium, 1159 of which had microalbumi-
nuria. Significant association was again found with both 
UACR (p = 0.005) and the presence of microalbuminuria, 
indicating the influence on albuminuria is independent 
of ethnicity. However larger studies in a wider range of 
ethnically diverse populations may provide confirmation 
[60].
As well as showing significant association with eGFR, 
SHROOM3 (rs17319721) was also identified as being 
significantly associated with UACR in a combined meta-
analysis of 31,580 and 27,746 Caucasian patients from 
independent cohorts within the CKDGen Consortium 
[60]. As this SHROOM3 variant has also been associated 
with larger impact on eGFR in patients with albuminu-
ria [4] it may imply that shroom3 has a functional role in 
proteinuria.
GWAS have also been used to explore other kidney 
diseases, as shown in Table 4. Association of HLA-DQA1 
and PLA2R1 has been shown in different studies of MGN 
patients. Both genes were first associated with MGN in 
three independent cohorts of Caucasian patients versus 
race-matched controls [63]. Replication of these findings 
also revealed that while PLA2R1 only showed association 
with MGN (p = 1.9 × 10−8), but HLA-DQA1 was signifi-
cantly associated with other renal immune disorders in 
addition to MGN (p = 5.9 × 10−27): LN (p = 2.8 × 10−6), 
T1DM with CKD (p = 6.9 × 10−5) and FSGS 
(p = 5.1 × 10−5) [64]. As IgAN is more common in Asian 
individuals [65], many studies have focused on studies of 
Asian cohorts, to determine if genetic variants give rise 
to higher disease incidence (Table 4). A combined analy-
sis of 3144 patients and 2822 controls from one European 
and two Han Chinese cohorts identified five genomic loci 
significantly associated with IgAN, most of which are 
involved in innate immune responses [66]. These results 
were replicated in a meta-analysis of 12 cohorts com-
prising 5372 cases and 5383 controls of either European, 
East Asian or African American ethnicity [67]. Twelve 
SNPs within the five previously reported genomic loci 
(CFHR3/R1, HLA DQB1/DRB1, TAP2/PSMB9, DPA1/
DPB2, HORMAD2) were found to reach genome-wide 
significance (p < 5.0 × 10−8) [67]. A study comprising 
7658 cases and 12,954 controls of East Asian or Euro-
pean origin replicated all previously reported IgAN-
associated variants and identified several new ones [68]. 
These include new variants within the previously identi-
fied HLA-DQ/DR locus (rs7763262, p = 1.8 × 10−38) [66], 
and the newly identified rs11574637 variant in ITGAX-
ITGAM  (p = 2.8 × 10−1). Variants within the HLA and 
ITGAX-ITGAM loci have been identified in patients with 
other autoimmune disorders, such as rheumatoid arthri-
tis [69] and systemic sclerosis [70], respectively. A study 
of 8313 Han Chinese cases and 19,680 controls found sig-
nificant association the ST6GAL1 (p = 7.27 × 10−10), ACC
S (p = 3.93 × 10−9), ODF1-KLF10 (p = 1.41 × 10−9) genes, 
as well as three independent variants in the  DEFA gene 
(rs2738058, p = 1.15 × 10−19; rs12716641, p = 9.53 × 10−9; 
rs9314614, p = 4.25 × 10−9) [71]. The association of a pre-
viously reported ITGAX-ITGAM  variant was also vali-
dated (p = 2.26 × 10−19) [68, 71].
Conclusions
Although several genes with strong associations to renal 
diseases, eGFR and UACR, have been identified, the 
development of a universal diagnostic gene biomarker 
panel is however challenged by the variability and eth-
nic specificity of many of the variants identified. While 
GWAS may provide insights to genetic causes of disease, 
little information regarding the functional implications 
of the identified SNPs can be derived. Further analyses 
such as epigenomic and transcriptomic profiling, cou-
pled with protein and metabolite analysis may give a 
more complete picture of CKD. A multi-omic approach 
may add functional and physiological evidence for the 
use of GWAS-identified variants as biomarkers or lead to 
the identification of biomarkers of a different nature that 
have not been detected through GWAS.
Epigenetic biomarkers
Epigenetics is defined as, “the study of changes in gene 
function that are mitotically and/or meiotically heritable 
and that do not entail a change in DNA sequence” [72]. 
Epigenetics acts as a bridge between genotype and phe-
notype, helping to explain why some genetic alterations 
may not necessarily result in an altered phenotype. It is 
therefore extremely important to consider epigenomic 
biomarkers alongside genomic and transcriptomic analy-
ses to discover the role of different pathways in disease, 
as change in gene expression may not be linked solely to 
genetic aberrations and therefore will not be detected 
using purely genetic analysis.
Epigenetics can be subdivided by mechanism. Cova-
lent modifications of DNA and histone proteins, such 
as DNA methylation, and the action of non-coding 
RNAs, such as microRNAs (miRNAs), all seek to inter-
fere with gene expression without changing the genetic 
sequence of the gene in question, including any of its 
promotor or enhancer regions. Epigenetic regulation 
of gene expression results in altered levels of target 
gene mRNA available for translation, and thus affects 
protein synthesis. Epigenetic regulation is required 
to maintain the regulation of gene activity, transcrip-
tion and contributes to the maintenance of genomic 
stability [73]. However, epigenetic dysregulation has 
previously been linked to diseases like Prader–Willi 
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syndrome, an imprinting disorder, Fragile X syndrome, 
caused by loss of genomic stability and multiple differ-
ent cancers [74]. Evidence has suggested that loss of 
epigenetic control may be associated with CKD, with 
differential expression of microRNAs [75] and differ-
ential DNA methylation detected in kidney fibrogen-
esis, a hallmark of CKD [76].
DNA methylation
DNA methylation is an example of a covalent modifica-
tion to the DNA sequence that has the ability to alter 
gene transcription, especially if found near the promoter 
or enhancer regions of genes [77, 78]. DNA methylation 
is the transfer of a methyl group (-CH3) from S-adeno-
sylmethionine to the fifth carbon of a cytosine nucleotide 
in the DNA sequence [79], catalysed by DNA methyl-
transferases (DNMTs) [80, 81]. It is the presence of these 
cytosine-bound methyl groups that can either prevent 
the binding of transcription factors in the promoter 
region of genes, or attract and bind repressor proteins, 
both of which lead to a reduction in gene transcription. 
The majority of methylated cytosines are followed by a 
guanine nucleotide and these sites have been denoted as 
CpG sites [82]. Most of CpG sites are methylated, except 
in regions of high CpG density, known as CpG islands. 
CpG islands exhibit much lower levels of DNA methyla-
tion than expected, with methylation found to be signifi-
cantly lower in these regions when compared to other 
genomic CpG sites [83]. CpG islands are often found at 
gene promoters, and their methylation regulates gene 
expression [84]. DNA methylation has been shown to be 
involved in maintaining X-inactivation [85], the silenc-
ing of imprinted genes [86], and plays a role in embry-
onic development; knockout of DNMT enzymes in mice 
results in embryonic lethality [87, 88]. The role of DNA 
methylation in diseases like cancer is clear, with colorec-
tal, breast and renal cancers all showing high levels of 
epigenetic dysregulation [89].
Role of DNA methylation in CKD
Multiple approaches have been taken to further under-
stand the role of epigenetic aberrations in the patho-
genesis of CKD (Table  5). Global methylation profiling 
[90–93], epigenome-wide association studies [94–101] 
and candidate gene studies [91, 102, 103] have been car-
ried out in patients with CKD, DKD and ESRD. Detec-
tion of differential DNA methylation in these studies may 
lead to new diagnostic and prognostic epigenetic bio-
marker panels being developed.
Global methylation and  CKD The influence of total 
genomic methylation levels on CKD has been analysed 
by global methylation analysis. Global methylation can be 
assessed by different methodologies; enzymatic digestion 
with methylated and unmethylated cytosine-sensitive 
enzymes generates a methylation ratio using the lumi-
nometric methylation assay (LUMA), percentage meth-
ylation can be established using a combination of liquid 
chromatography and mass spectrometry (LC-MS) or 
surrogate markers of whole genome methylation may be 
used [104]. An example of the latter is pyrosequencing the 
long-interspersed nuclear element 1 (LINE-1), which is 
considered a reliable marker of global methylation [104, 
105].
In the first study of global methylation in CKD, LUMA 
was used to evaluate 155 patients with CKD (stage 3–5) 
and 36 healthy controls [90]. A differential methyla-
tion ratio was found for inflammation in late-stage CKD 
patients CKD (p = 0.0001) [90]. While this study showed 
no significant difference for CKD itself, other stud-
ies attempted to demonstrate differential global meth-
ylation in CKD, with mixed success. Pyrosequencing of 
the LINE-1 element in 22 ESRD patients and 26 healthy 
controls showed that this retrotransposon was signifi-
cantly hypermethylated (p < 0.01) in ESRD patients [91]. 
Although all ESRD patients also had hypertension, this 
is not known to be associated with global hypermeth-
ylation, being either associated with global loss of meth-
ylation [106] or with no difference in methylation at the 
LINE-1 transposable element [107]. While this study 
found significant hypermethylation associated with 
ESRD, another study focusing on the association between 
DNA methylation and renal function in 93 CKD patients 
(stage 2–4) found no significant association of DNA 
methylation with renal function [93]. Indeed, a more-
recent study found significant DNA hypomethylation 
(p = 0.0001) in 30 Stage 3–4 CKD patients and demon-
strated the ability of cholesterol lowering agents to sig-
nificantly increase DNA methylation [92].
No clear association of CKD with global changes in 
DNA methylation has been established from these stud-
ies. Published studies of global methylation have reported 
on patient groups with small numbers (n < 100) and such 
studies lack power to detect significant differences in 
global DNA methylation.
Site‑specific differential methylation in  chronic kidney 
disease In the last 10  years, research has been under-
taken to identify individual genes or genomic regions 
whose differential methylation is associated with CKD; 
several groups have utilised large, array-based methods 
to analyse DNA methylation at an epigenome-wide level. 
The Illumina Infinium HumanMethylation 450  K Bead-
Chip (450 K Array) is used to assess methylation status of 
485,577 genomic CpG sites [108], while next-generation 
methylation sequencing (Methyl-Seq) assesses the meth-
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ylation status of 813,267 CpG sites [109]. These large, 
array-based methods allow much higher sample through-
put, contrasting with traditional techniques for assessing 
methylation like pyrosequencing, where only a fraction of 
the CpG sites can be assessed in the same time-frame.
Using the 450  K array, 23 unique genes were identi-
fied in a sample of 255 CKD patients that contained 
more than one significantly differentially methyl-
ated CpG site (p < 10−8) [97]. Of these genes, six were 
selected to undergo RNA analysis. While some genes, 
such as ELMO1, showed altered levels of expression 
in CKD patients, these differences did not reach sig-
nificance. So while this may suggest that DNA methyla-
tion plays a role in regulating their expression, further 
analysis is required in a larger number of patients, as 
only two Stage 5 CKD patients and two controls were 
used in expression studies [97]. Further study in this 
group of patients was focused on the differential meth-
ylation of the UMOD and related genes UMODL1 and 
UMODL1-AS1 genes [100], previously associated with 
CKD in GWAS [23, 25]. Indeed, 11 CpGs across the 
three genes were found to be significantly differentially 
methylated in patients with CKD (p < 10−8) [100].
The relationship between DNA methylation and CKD 
progression has also been assessed in Stage 2–4 CKD 
patients. Twenty patients with “rapid disease progres-
sion” and 20 patients with “stable kidney function,” 
determined using a mixed effects linear regression 
model using two measures of eGFR, had their meth-
ylation status assessed using the 450  K Array [98]. 
Although no significant association with CKD progres-
sion could be found after correction for multiple test-
ing, several candidate genes (including UMODL1) that 
had previously been related with CKD in the literature 
[96, 98, 100] showed a trend towards association with 
rapid CKD progression.
Differential methylation of single genes has also been 
studied, particularly when they are candidate to have a 
functional role in the development of CKD. In a study of 
96 ESRD patients/96 controls, the specific methylation 
of the methylenetetrahydrofolate reductase (MTHFR) 
gene promoter was found to be significantly associated 
with ESRD (p = 0.003) and significant correlation was 
observed between a lower eGFR and MTHFR promoter 
methylation (p = 0.026) [102]. The hypermethylation of 
the MTHFR promoter is thought to lead to the transcrip-
tional silencing of MTHFR, preventing remethylation 
of S-adenosylhomocysteine to S-adenosylmethionine, 
which is required to donate methyl groups necessary 
in DNA methylation [110]. Loss of MTHFR activity is 
characterised by a build-up of S-adenosylhomocysteine, 
resulting in hyperhomocysteinaemia in patients—which 
is strongly associated with CKD [111]. However, MTHFR 
was also highlighted in two other analyses, with Sapienza 
et al. and Ko et al. both finding significant hypomethyla-
tion of the MTHFR gene in patients with ESRD and DKD 
and solely DKD, respectively [95, 96]. This contrasts with 
the hypermethylation of the gene promoter found in the 
original study. Therefore, as the evidence of MTHFR as a 
biomarker for CKD remains conflicting, its usefulness in 
any panel of non-invasive epigenetic biomarkers remains 
controversial [95, 96, 102].
Significant hypomethylation at the promoter of SHC1, 
formerly known as P66SHC (Gene ID: 6464), was found 
in 22 patients with ESRD (p < 0.01) [91]. SCH1 is involved 
in the regulation of reactive oxygen species [112] and 
may be linked to CKD due to oxidative stress has been 
shown increased in patients with CKD [113].
Klotho (KL) is another gene that has been assessed 
on an individual basis in CKD patients. KL is highly 
expressed in kidney tissues, and causes a syndrome simi-
lar to CKD when it is knocked out in mice [114]. Both 
KL mRNA and protein production have been found to 
be reduced significantly in patients suffering from ESRD 
[115]. Using pyrosequencing, six CpG sites across the 
KL gene in peripheral blood DNA and DNA extracted 
from renal tissue of 47 patients were analysed [103]. 
Forty-seven renal cell carcinoma biopsies and periph-
eral blood DNA of 48 healthy patients acted as non-CKD 
control samples. KL was significantly hypermethylated in 
approximately 70% of all renal and blood samples taken 
from patients (p < 0.001), and KL promoter hypermeth-
ylation also found to be inversely correlated with eGFR 
[103]. For this reason, KL has been further investigated 
in animal and in  vitro models to determine if KL pro-
moter hypermethylation is involved in the development 
of CKD and altered renal fibrosis was noted in cells with 
KL hypermethylation [116, 117].
Association with diabetic kidney disease
To date, several studies have investigated the role of 
methylation in DKD and diabetic ESRD, as shown in 
Table 6 [94–96, 101].
Two different studies have used the Illumina Infinium 
HumanMethylation27 BeadChip (27 K Array) to assess 
the methylation status of 27,578 CpG sites in patients 
with DKD and diabetic ESRD [94, 95]. Bell et al. exam-
ined differences in DNA methylation in genomic DNA 
extracted from whole blood from 96 DKD patients and 
96 controls [94], while Sapienza et al. focussed on dif-
ferential methylation in DNA extracted from saliva of 
23 diabetic ESRD patients and 23 controls [95]. Bell 
et  al. found over 400 differentially methylated CpGs 
originally, which were reduced to 19 when corrected 
for multiple testing. Sapienza et  al. found 187 genes 
containing more than one significantly differentially 
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methylated CpG, but several of these genes were elimi-
nated as false-positives after correction. There were no 
common genes identified between these two groups. 
Although they used the same methylation analysis, 
this is perhaps not surprising, since Sapienza studied 
patients with diabetic ESRD, whereas Bell only analysed 
patients with DKD, and both studies were very small. 
Ethnic differences in cohorts may also have played a 
role; Bell et  al. analysed samples from Irish patients 
[94], where Sapienza examined African American and 
Hispanic American patients [95]. Indeed, when His-
panic patients were removed from the analysis, the 
number of genes detected as being differentially meth-
ylated was reduced, showing that ethnicity may influ-
ence on the genes detected [95]. While these studies 
have not provided clear differentially methylated can-
didate genes, they have highlighted the need for studies 
with greater statistical power and that the future of epi-
genome-wide studies may lie in the analysis of specific 
phenotypes within well-defined patient populations.
By far the most extensive list of differentially meth-
ylated genes in DKD has been produced by Ko et  al. 
where 14 patients were compared to 14 controls in a 
discovery analysis, which was followed up by a repli-
cation study consisting of 21 patients and 66 controls 
[96]. There were marked differences in phenotypes 
between the discovery and replication patient groups; 
the discovery cohort had both hypertension and DKD 
patients, and controls were healthy subjects, whereas 
the replication cohort consisted of a DKD patient 
group and non-DKD control group, including patients 
with hypertension and diabetes. They identified 1061 
unique differentially methylated genes in the replica-
tion cohort, 98% of which had also been found in the 
discovery analysis. Of the 2% of genes only found in the 
discovery cohort, CUX1, PTPRN2 and STK24 had pre-
viously been associated with CKD [97] and the associa-
tion of SALL1 and WHSC1 were later confirmed in cells 
extracted from non-diabetic ESRD patients [99]. These 
genes were not found to be associated in the replica-
tion analysis, suggesting that even subtle phenotypic 
differences may give rise to differences in DNA meth-
ylation. Further analysis would be required to deter-
mine the contribution of specific phenotypes to the 
significance associated with CpGs in these genes. The 
larger number of significant differentially methylated 
CpGs detected in this study may also be due to the use 
of renal tubule cells as opposed to genomic DNA from 
whole blood extracted in all previous epigenome-wide 
analyses.
RUNX3 and PHB have been described in multiple stud-
ies analysing differential methylation in DKD. RUNX3 
was found to be significantly differentially methylated by 
Ko et al. and Bell et  al. and in fact was the only unique 
gene that remained significant after the application of 
a more stringent false discovery rate threshold [94, 96]. 
RUNX3 is a transcription factor that works in balance 
with the STAT5 transcription factor in the renal fibrosis 
pathway [118], suggesting that altered methylation and 
thus expression of RUNX3 may lead to aberrant renal 
fibrosis, a hallmark of CKD [119]. PHB, a mitochondrial 
gene, was identified by both Ko et al. and Swan et al. Swan 
et  al. found PHB significantly differentially methylated 
in 150 DKD patients, 50 of whom were diabetic ESRD 
patients, and significance was reached for PHB in both 
groups when compared to diabetic controls [101]. The 
sub-analysis in mitochondrial genes showed 51 genes dif-
ferentially methylated in DKD versus the diabetic control 
group (p < 10−8), and 374 genes were identified between 
the ESRD and diabetic control group [101]. Forty-three 
of these genes overlapped with the 51 genes found asso-
ciated with DKD, but PHB was the only gene overlapping 
with other studies [96, 101]. PHB has been involved in 
regulating cellular processes, such as transcription and 
apoptosis [120] and its dysregulation increases renal 
fibrosis and oxidative stress [121], which have previously 
been associated with CKD [113, 119].
In a non-population based study, further analysis of the 
epigenetic changes involved in ESRD was investigated. 
The genome-wide methylation of monocytes treated with 
either serum from patients with ESRD or healthy controls 
was assessed [99]. Although only performed in 5 patients 
and 5 healthy age- and sex-matched controls, differen-
tially methylated CpGs were detected between mono-
cytes that had differentiated in the presence of ESRD 
patient or control serum. The top 50 genes were listed 
and five of these (GPR39, HDAC1, PRKCE, SLC43A2 and 
ST3GAL5) overlapped with genes identified as significant 
in the replication analysis by Ko et al. [96, 99]. While this 
study seeks to replicate the changes in DNA methylation 
seen in uraemic ESRD patients rather than measuring 
DNA methylation in patients directly, overlapping results 
in DKD patients may prompt further investigation in this 
area in a large patient cohort to confirm results at popu-
lation level.
Additional work has been carried out by several groups 
to determine the functional implications of the signifi-
cant differences in methylation in CKD patients [96, 97]. 
Ko et  al. performed RNA and Gene Ontology analysis 
on the replication cohort and found that over 40% of 
the significantly methylated genes showed significant 
changes in gene expression. Many of these genes, such 
as TGFBR3 and SMAD6, belong to the TGF-β pathway, 
whose involvement in CKD development is well-estab-
lished [96]. Smyth et  al. carried out similar analysis on 
two patients and controls and although no significant 
Page 22 of 44Cañadas‑Garre et al. J Transl Med          (2018) 16:292 
changes in gene expression were found, pathway analysis 
linked several genes to the mucin type O-glycan biosyn-
thesis pathway, dysregulation of which has been shown to 
result in kidney abnormalities [97, 122]. However, despite 
this additional work, no genes or CpG sites have been 
established as a clear candidates to be taken forward into 
biomarker development [96, 97].
Conclusions
Altogether, these findings suggest a role for DNA methyl-
ation analysis in the diagnosis and prognosis of CKD and 
related diseases, but also highlight the difficulties asso-
ciated with establishment of definitive epigenomic bio-
markers. Among all the methylation markers described 
in the literature, only a few genes appear more than once. 
MTHFR gene is the only epigenetic biomarker proposed 
in more than two studies, but with inconsistent results 
regarding the mechanism underlying its influence [95, 
96, 102]. Therefore, the role of MTHFR as a potential bio-
marker in CKD is yet to be elucidated. Further investi-
gations using a larger number of CpG sites, phenotypes 
and ethnicities in larger cohorts is required to allow 
accurate, phenotype-specific epigenetic biomarkers to 
be established. Deeper understanding of the role DNA 
methylation plays in disease development may lead to the 
discovery of potential points of therapeutic intervention, 
as well as the discovery of diagnostic and prognostic bio-
markers. To better understand this, the identification of 
specific methylation regions in CKD is essential, to serve 
both as potential candidates for epigenomic biomarkers, 
but to also to give an indication of the genes affected in 
different functional pathways, giving rise to the elucida-
tion of mechanisms involved in the development of CKD.
microRNA
MiRNAs are 21–25 nucleotides length small non-coding 
RNA molecules, partially complementary to one or more 
messenger RNA (mRNA), which downregulate gene 
expression by translational repression, mRNA cleav-
age, and deadenylation. Targeted mRNAs include those 
involved in biological processes such as inflammatory 
response, cell–cell interaction, apoptosis and intra-cel-
lular signalling [123]. MiRNAs have been widely investi-
gated as diagnostic and prognostic biomarkers in CKD, 
with a particular interest in their potential use as non-
invasive markers.
Chronic kidney disease
Prediction of CKD Several studies have explored the use 
panels of differentially expressed miRNAs as potential 
biomarkers for CKD although these reported on relatively 
small numbers of patients (Table 7).
Recently, a panel composed of 16 miRNAs upregu-
lated (let-7c-5p, miR-222–3p, miR-27a-3p, miR-27b-3p, 
miR-296-5p, miR-31-5p, miR-3687, miR-6769b-5p, and 
miR-877-3p) or downregulated (miR-133a, miR-133b, 
miR-15a-5p, miR-181a-5p, miR-34a-5p, miR-181c-5p, 
and miR1-2) has been identified in urine exosomes of 15 
CKD patients compared to 10 healthy controls [124]. A 
similar 14 miRNAs panel (miR-29c-5p, miR-345-5p, miR-
142-3p, miR-339-3p were upregulated and miR-17-5p, 
miR-130a-3p, miR-15b-5p, miR-106b-3p, miR-106a-5p, 
miR-16-5p, miR-181a-5p, miR-1285-3p, miR-15a-5p, 
miR-210-3p were downregulated) has been described in 
15 African American CKD patients with treated hyper-
tension compared to 15 controls (non-CKD patients 
with treated hypertension) [125]. In contrast with these 
results, downregulation of members of miR-29 and miR-
200 was found in urine exosomes from 32 CKD patients 
when compared to 7 healthy controls [126].
Circulating miR-122 has been identified as a bio-
marker for ESRD, being substantially downregulated in 
17 pre-haemodialysis patients compared to 22 healthy 
controls (19-fold lower), 30 patients with CKD (21.7-
fold lower) and 15 transplanted patients [127]. Another 
biomarker differentially expressed in dialysis patients is 
miRNA-155, whose serum levels were found increased 
in 82 dialysis patients compared with 16 healthy sub-
jects (P < 0.05) [128]. Interestingly, miR-155, along 
with other miRNAs involved in CVD, such as miR-21, 
miR-26b, or miR-146b, had been found differentially 
expressed in 10 clinically stable haemodialysis patients 
compared to 10 healthy controls [129]. In a larger study, 
circulating levels of miR-125b, miR-145 and miR-155 
were found significantly decreased in 90 CKD and 10 
haemodialysis patients compared to those in 8 healthy 
volunteers [130]. Decreased circulating levels of the 
three miRNA were also associated with progressive loss 
of eGFR [130].
The miRNA transcriptome has also been studied in 
platelets from five chronic haemodialysis patients and 
five stage 4 CKD uremic patients and compared with 
five age- and sex-matched healthy subjects with normal 
renal function [131]. Upregulation of miR-19b, involved 
in platelet reactivity, was found in uraemic CKD patients.
eGFR and  CKD stratification Total circulating small 
RNA level has been found decreased in 53 patients with 
impaired kidney function (CKD stages 3–5) compared to 
22 controls (p < 0.0001, r = 0.553; Spearman rho) [132]. 
Furthermore, total small RNA concentration was three-
fold higher in plasma of normal/stage 3 patients compared 
to stage 4/ESRD (p < 0.0001). Specifically, the expressions 
of circulating miR-16, miR-21, miR-155, miR-210 and 
miR-638 were inversely correlated with eGFR [132]. Uri-
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nary miRNA level and kidney function was only associ-
ated for miR-638, which showed a significant increase in 
patients with stage 4 CKD compared to normal and stage 
3 CKD patients (p < 0.006) [132]. In agreement with these 
results, decreased circulating levels of miR-125b, miR-
145 and miR-155 were associated with progressive loss 
of eGFR by multivariate analyses in as study comprising 
100 CKD and 10 haemodialysis patients of Caucasian and 
African American origin [130]. eGFR also inversely cor-
related with urinary level of miR-155 in 60 nephrolithiasis 
patients compared with 50 controls [133].
Another miRNA example associated with eGFR is miR-
29c, which correlated with both eGFR (r = 0.362; p < 0.05) 
and degree of tubulointerstitial fibrosis (r = − 0.359; 
p < 0.05) in a group of 32 CKD patients [126].
More recently, 384 urinary and 266 circulatory miRNAs 
were found differentially expressed in 28 CKD patients 
when grouped by eGFR ≥ 30 vs. < 30  ml/min/1.73  m2 
[134]. Among them, TGF-β signaling-related mRNA 
targets suggest that specific urinary and plasma miRNA 
profiles may act as diagnostic and prognostic biomark-
ers in CKD [134]. Urine downregulation of Let-7a and 
upregulation of miR-130 may identify eGFR < 30  ml/
min/1.73 m2 patients, whereas upregulation of miR-1825 
and miR-1281 in both urine and plasma, and plasma 
miR-423 downregulation would serve as an indicator of 
decreased eGFR [134].
Diabetic kidney disease
Prediction of  DKD Table  8 shows miRNA studies 
focused on DKD. The development of microalbuminuria 
was associated with a urinary miRNA signature composed 
of miRNAs known to be involved in the pathogenesis and 
progression of diabetic renal disease (miR-105-3p, miR-
1972, miR-28-3p, miR-30b-3p, miR-363-3p, miR-424-5p, 
miR-486-5p, miR-495, miR-548o-3p and for women 
miR-192-5p, miR-720) in 17 T1DM patients exhibiting 
microalbuminuria compared to 10 T1DM without renal 
disease [135]. The same group had described a decrease 
in urine expression of miRNA-221-3p in a former study 
of T1DM patients with [10] or without DKD [10, 136]. In 
these patients, a panel of 10 miRNAs (underexpressed: 
miR-221-3p; overexpressed: miR-619, miR-486-3p, miR-
335-5p, miR-552, miR-1912, miR-1224-3p, miR-424-5p, 
miR-141-3p, miR-29b-1-5p) was identified for patients 
with overt DKD [136]. Furthermore, downregulation of 
miR-323b-5p and upregulation of miR-122-5p was asso-
ciated with persistent microalbuminuria. Appearance of 
microalbuminuria was associated with decreased miR-
323b-5p and increased miR-429 urine levels [136]. Con-
sistent with these findings, downregulation of miR-155 
and miR-424, and upregulation of miR-130a and miR-145 
was found in urinary exosomes from 12 microalbuminu-
ric T1DM compared with 12 normoalbuminuric patients 
[137].
eGFR In the largest miRNA study to date in DKD 
patients, downregulation of miR-2861, miR-1915-3p, 
and miR-4532 was associated with eGFR (p < 0.01) and 
interstitial fibrosis/tubular atrophy (p < 0.05) [138]. In 
a separate study, miR-192 downregulation was corre-
lated with tubulointerstitial fibrosis and low eGFR in 22 
DKD patients especially in those who had stage 5 CKD 
or required renal replacement therapy within 6 months of 
their renal biopsy [139].
The rate of eGFR decline positively correlated with 
the urinary miR-21 (r = 0.301; p = 0.026) and miR-216a 
(r = 0.515; p < 0.0001) in a combined analysis of patients 
with diverse CKD aetiologies including IgAN, diabetic 
glomerulosclerosis and hypertensive nephrosclerosis 
[140]. However, the separate analysis by disease only 
found urinary miR-216a levels correlated with the rate of 
eGFR decline in patients with hypertensive nephroscle-
rosis (r = 0.588; p = 0.005) and diabetic glomeruloscle-
rosis (r = 0.605; p = 0.010) [140]. Other urinary miRNA 
biomarkers correlated with eGFR in IgAN patients are 
miR-200b (r = 0.512; p < 0.001) and miR-429 (r = 0.425; 
p = 0.005) [141]. In systemic lupus erythematous (SLE) 
patients, eGFR was correlated with urinary miR-146a in 
two studies from the same group (r = 0.242; p = 0.008) 
[142, 143]. Serum miR-146a also inversely correlated 
with proteinuria (r = − 0.341; p = 0.031) and the SLE 
Disease Activity Index (r = − 0.465; p = 0.003) in 40 SLE 
patients [142].
Primary glomerulonephritis
Although many studies have tried to find a specific signa-
ture of miRNAs in primary glomerulonephritis (Table 9), 
most of them are small sized cross-sectional designs 
which lack the statistical power and appropriate treat-
ment of important issues, as correction for multiple test-
ing, complicating the generalisation of their conclusions 
and limiting the extrapolation of their results.
Overexpression of miR-25-3p, miR-144-3p or miR-
486-5p in urinary erythrocytes was recently proposed as 
non-invasive diagnostic biomarkers for IgAN nephropa-
thy in a study of 93 IgAN patients compared to 82 normal 
subjects and 40 disease controls [144].
Downregulation of miR-30d, miR-140-3p, miR-532-3p, 
miR-194, miR-190, miR-204 and miR-206 was associ-
ated with progression to ESRD or doubling of SCr in 43 
patients with various glomerular diseases and decreased 
expression of miR-206 and miR-532-3p was confirmed 
in a validation cohort of 29 patients [123]. When the 
miRNA expression in the urinary sediment of 56 
patients who had undergone kidney biopsy (17 diabetic 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 32 of 44Cañadas‑Garre et al. J Transl Med          (2018) 16:292 
glomerulosclerosis, 17 IgAN and 22 with hypertensive 
nephrosclerosis) was quantified, decreased miR-15 was 
associated with diabetic glomerulosclerosis, whereas 
increased miR-17 levels were shown in IgAN [140].
Other miRNA biomarkers proposed as indicators 
of IgAN are urinary and intra-renal overexpression of 
miR-146a and miR-155, described in 43 patients with 
IgAN compared to 13 healthy volunteers [145], urinary 
downregulation of miR-200a, miR-200b and miR-429 of 
patients with IgAN [141] and upregulation of miR-148b 
in PBMCs of patients with IgAN [146].
In 16 patients with FSGS, urinary downregulation 
of miR-1915 and miR-663 and miR-155 upregulation 
was found in patients when compared to five individu-
als with minimal change disease and five healthy con-
trols (p < 0.001 and p < 0.005, respectively) [147]. Urinary 
levels of miR-663 were inversely correlated with eGFR 
(r = − 0.50; p < 0.04). Proteinuria correlated with higher 
plasma levels of miR-342 (r = 0.73; p = 0.02) and higher 
urine levels of miR-155 (r = 0.72; p = 0.03) and miR-663 
(r = 0.45; p = 0.04), and with lower urinary levels of miR-
1915 (r = 0.95, P = 0.003). These patients also showed 
upregulation of miR-30b, miR-30c, miR-34b, miR-34c 
and miR-342 in plasma and mir-1225-5p in urine [147]. In 
another study, an initial screening stage including plasma 
from nine FSGS patients and nine healthy controls iden-
tified a panel of three upregulated miRNAs (miR-125b, 
miR-186, and miR-193a-3p); the panel was subsequently 
confirmed in 32 FSGS patients and 30 healthy controls 
[148]. Increased plasma levels of miR-125b and miR-186 
were also associated with nephrotic proteinuria [148]. 
Other proposed biomarkers for FSGS and kidney injury 
are miR-10a and miR-30d, which were found increased 
about 13- and 10-fold, respectively in the urine from 10 
FSGS patients compared to 16 healthy controls [149].
Other kidney diseases
Table  10 shows miRNA studies developed in patients 
with other kidney diseases. Lupus disease activity has 
been associated with other biomarkers, such as miR-221 
and miR-222, in the urinary sediment of 12 patients with 
LN [150]. These biomarkers have also been associated 
with macroalbuminuria in DKD patients [136] and CKD 
[124, 125]. Serum downregulation and urine upregulation 
of miR-146a and miR-155 was described in SLE patients 
compared to controls in two studies from the same group 
[142, 143]. Also in LN, downregulation of miR-3201 and 
miR-1273e (> threefold; p < 0.0001) and association with 
endocapillary glomerular inflammation was found in 89 
LN patients (p < 0.01) [138].
Urinary overexpression of miR-142-3p, associated with 
CKD [125], has also been found in 41 kidney transplant 
recipients (23 patients with acute rejection and 18 with 
acute tubular necrosis when compared to eight stable 
patients (p < 0.001 and p < 0.005, respectively) [151]. 
Peripheral blood analysis in these patients also showed 
overexpression of miR-142-3p as a marker of acute tubu-
lar necrosis (p < 0.05 for both acute tubular necrosis/
stable and acute tubular necrosis/acute rejection com-
parisons) [151].
Serum and urinary levels of miR-155 were found sig-
nificantly higher in 60 nephrolithiasis patients compared 
with 50 controls [133]. miR-155 has also been associated 
with eGFR in CKD [130, 132, 133], proteinuria in FSGS 
[147], microalbuminuria in DKD [137], and proposed as 
diagnostic biomarker of CKD [129, 130, 148], FSGS [147] 
and IgAN [145].
Conclusions
In the last decade, there have been major research efforts 
to find miRNA biomarkers capable of identifying and 
stratifying kidney diseases and associated phenotypic fea-
tures, such as eGFR and proteinuria. Arguably the most 
promising miRNA biomarker associated with kidney 
diseases is miR-155, which is inversely correlated with 
eGFR, and found differentially expressed in CKD, IgAN, 
FSGS and nephrolithiasis. MiR-29 has also been found in 
several studies associated with CKD, overt albuminuria 
in DKD and nephrotic syndrome. However, the findings 
regarding whether its expression is up- or downregulated 
in CKD are conflicting, although these differences may be 
due to the sample source used, blood or urine exosomes. 
Other miRNA biomarkers proposed for kidney disease 
(miR-16, miR-17, miR-21, miR-30b, miR-122, miR-130, 
miR-142-3p, miR-146, miR-200, miR221, miR222, miR-
486, miR-1915) have not been confirmed in more than 
two independent studies, indicating that further investi-
gation needs to be done to clarify their role.
Transcriptomics
Transcriptomics is the study of the complete set of RNA 
transcripts produced by the genome, in a specific cell 
or under certain circumstances [152]. The sum of RNA 
transcripts including mRNAs, ribosomal and transfer 
RNA, and regulatory noncoding RNAs comprise the 
transcriptome [153]. Throughout the past two decades, 
transcriptomics studies on renal disease have been car-
ried out using different approaches, either studying the 
entire transcriptome or focusing on individual biomark-
ers. Since 1994, over 80 papers have tried to identify key 
regulators of different pathways which influence renal 
disease, including CKD, ESRD, DKD, Primary Glomer-
ulonephritis, SLE and various other renal conditions. 
Most of the studies were performed on small numbers, 
with only three studies analysing results from over 100 
patients (Table  11). A recent integrative bioinformatics 
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analysis of 250 gene expression datasets of healthy renal 
tissues and those with various types of established CKD, 
including DKD, hypertensive nephropathy, and glomeru-
lonephritis, retrieved from the Gene Expression Omni-
bus repository (https ://www.ncbi.nlm.nih.gov/geo/) has 
identified nine genes significantly differentially expressed 
both in diseased glomeruli and tubules (IFI16, COL3A1, 
ZFP36, NR4A3, DUSP1, FOSB, HBB, FN1, PTPRC) [154]. 
Gene Ontology, pathway enrichment analysis and pro-
tein interaction network showed dysregulation of sev-
eral metabolic, immune response, signalling pathways, 
platelet dysfunction, and extracellular matrix (ECM) 
organization in the glomeruli and signalling pathways in 
the tubules, mainly associated with apoptosis, PI3K-Akt, 
MAPK, and TGF-β [154].
Chronic kidney disease
The association of mRNA expression profiles with the 
risk of CKD has been investigated in different such as 
human renal biopsies, urine or peripheral blood samples.
Urine samples were used to investigate the correla-
tion of the mRNA expression of a panel of target genes 
with renal function in 29 CKD patients (12 IgAN and 17 
glomerulosclerosis) and 10 healthy controls using qRT-
PCR [155]. Overexpression of TGF-β and MCP-1 was 
associated with glomerulosclerosis, and overexpression 
of collagen IV with both types of CKD. TGF-β1 plays 
an important role in the pathogenesis of CKD as it pro-
motes inflammatory cell infiltration, tubular cell atrophy, 
mesangial cell hypertrophy and podocyte apoptosis [156], 
key features of CKD [157]. Urinary expression of connec-
tive tissue growth factor (CTGF) (r = − 0.471, p = 0.010) 
and collagen I (r = − 0.399, p = 0.032) were inversely cor-
related with the rate of eGFR decline after 12  months 
of follow-up, while TGF-β and MCP-1 did not have an 
influence on eGFR. CKD is characterized by the accumu-
lation of ECM components in the glomeruli (glomerular 
fibrosis, glomerulosclerosis) and the tubular interstitium 
(tubulointerstitial fibrosis) [156]. TGF-β, IL-6 and MCP-1 
expression was correlated to TLR4, which was signifi-
cantly upregulated in human kidney biopsies from 70 
CKD patients showing severe proteinuria and chronic 
ischaemic renal damage [158]. Both urinary and tissue 
MCP-1 also showed an increase in patients with acute 
renal inflammation in 174 patients with a variety of kid-
ney diseases [159].
IL-6 expression was higher in 75 stage 2–5 CKD 
patients compared with 33 normal subjects, although it 
was not dependent on stage [160]. These CKD patients 
also showed upregulation of TNF-α, which was inversely 
correlated with eGFR [160].
The mRNA levels of COX6C, COX7C, ATP5ME, 
and  UQCRH  in peripheral blood mononuclear cells 
(PBMC) were all significantly higher in CKD stage 4–5 
patients compared to nine CKD stage 2–3 patients and 
eight healthy controls [161].
Intrarenal mRNA expression of epidermal growth 
factor (EGF) in the tubulointerstitial compartment of 
kidney biopsies was identified as a potential predictive 
biomarker of eGFR at the time of the biopsy in 55 CKD 
patients [162].
Leukocyte angiotensin II AT1 receptor mRNA expres-
sion was inversely correlated with renal function in 20 
CKD patients compared to 10 healthy subjects  (r2 = 0.15, 
P < 0.03) [163].
Increased levels of versican expression positively cor-
related to histologic damage scores and to renal function 
in proteinuric kidney disease and impaired renal function 
in 74 renal biopsies from patients with various proteinu-
ric kidney diseases. Versican isoforms V0 and V1 signifi-
cantly correlated with SCr levels [164].
In 64 human kidney biopsies from CKD patients, 
mRNA expression of peroxisome proliferator-activated 
receptor gamma (PPARγ) correlated inversely with renal 
function [165]. In 35 CKD patients, urinary mRNA of 
CTGF and nephroblastoma overexpressed (NOV) gene 
were overexpressed compared to 12 healthy controls 
[166].
End‑stage renal disease
In 2006, Szeto analysed the role of urinary mRNA expres-
sion of 11 target genes as non-invasive markers on risk 
stratification of CKD patients in 131 patients with CKD 
followed until a primary endpoint of doubling SCr con-
centration or ESRD [155]. Urinary mRNA expression of 
hepatocyte growth factor was an independent predictor 
of the primary endpoint after adjustment for clinical and 
histological factors such as eGFR, gender and age and 
tubulointerstitial fibrosis [155].
Overexpression of IFN-γ, perforin, and granzyme B in 
 CD4+CD28null cells was associated with CKD in a study 
of 25 stage 4–5 CKD patients and 8 healthy subjects 
[167]. Higher expression of S100A12 in uraemic leuko-
cytes has also been proposed as biomarker for ESRD in 
40 stage 4–5 CKD patients compared to 20 healthy indi-
viduals (78.5 ± 70.5 vs. 23.7 ± 19.2  ng/ml; p = 0.0035) 
[168].
Diabetic kidney disease
Diabetes, as one of the leading causes of ESRD [169], has 
also been the focus of transcriptomic biomarkers studies.
The role of two isoforms of protein kinase C (PKC)-
alpha and beta, was investigated in renal biopsies using 
reverse transcription-PCR in 20 patients with T2DM. 
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PKC-alpha gene expression was increased in diabetic 
patients with CKD [170].
Peripheral blood samples were analysed for expression 
of 35 gene transcripts. The results showed that serum 
MCP-1, FGF-2, VEGF, and EGF were all elevated at every 
stage of DKD. However, serum IL2RA was the only medi-
ator to show a linear increase with the disease severity 
consistent with decreasing eGFR. The peripheral blood 
samples showed elevated levels of ICAM1, TNF-α, TGF-
β, IL-8, IL17RA, IFNγ, and MYD88 at all stages of disease 
in this sample of 20 patients with clinical or biopsy con-
firmed DKD age, race and gender matched with healthy 
volunteers [169].
Other renal diseases
Other CKD aetiologies, such as LN, have been inves-
tigated as potential beneficiaries of RNA expression 
biomarkers. CTGF mRNA expression was significantly 
correlated with TGF-β1, but inversely correlated with 
baseline eGFR, being higher in CKD stage 3–5 patients 
compared to stage 1–2 CKD in 39 patients with LN [171]. 
CTGF expression was positively associated with TGF-β1 
[171].
Higher TGF-β1 expression was suggested to be associ-
ated with IgAN progression, it was significantly associ-
ated with eGFR at the time of biopsy in 51 patients [172]. 
Upregulation of TNFRSF13B and  TNFRSF17 in B-lym-
phocytes appeared to be a trend in IgAN patients how-
ever statistical significance was not reached [173].
TNFAIP3 expression has been found downregulated 
in CD4+ T cells from SLE patients compared to normal 
controls [174].
Conclusion
Many studies have attempted to find transcriptomic 
biomarkers associated with a higher risk of CKD or 
biomarkers that predict changes in eGFR or proteinu-
ria. However, most of the studies are limited in sample 
size and power and the biomarkers are not replicated in 
other studies. Expression of some cytokines as TGF-α 
and TGF-β1 and the matricellular protein CTGF have 
been proposed in different studies as potential biomark-
ers of renal function in CKD, but the evidence is not 
overwhelming.
Concluding remarks
The proliferation of studies on omics-related biomarkers 
in the past decade reflects the need for novel, valid, non-
invasive tools capable of identifying persons at risk of 
CKD and helping to target the management of renal dis-
ease. Identification of undiagnosed disease, stratification 
of patients and monitoring of kidney disease are fields 
that would benefit of such validated biomarkers.
Several genes, including UMOD, SHROOM3 and 
ELMO1 have been strongly associated with renal dis-
eases, and some of their traits, such as eGFR and 
creatinine. The role of epigenetic and transcriptomic bio-
markers in CKD and related diseases is still unclear. Mul-
tiple putative biomarkers have been identified but these 
are mainly derived from small, single centre studies. Con-
firmation of the utility of such biomarkers is needed in 
separate populations and in larger cohorts.
It is very unlikely that a single biomarker can be identi-
fied that can improve CKD risk prediction beyond cur-
rent clinically used tests such as serum creatinine or 
urinary albumin excretion. Future progress in this area 
will come from combining multiple biomarkers into clas-
sifiers, including genomic, epigenomic, proteomic and/
or metabolomic profiles, to allow more precision in the 
diagnosis of CKD and in assessing the prognosis for renal 
disease.
Screening for CKD by eGFR and/or albuminuria in 
high-risk populations, e.g. DM or hypertension has been 
suggested to be cost-effective, whereas screening in the 
general population is only cost-effective in certain situa-
tions, for instance older patients or those with rapid CKD 
progression who could be targeted for RAAS inhibitors 
for renal and cardiovascular risk reduction [175]. The 
use of complementary molecular biomarkers to help in 
the identification of patients with potentially progres-
sive diseases, may delay the need of renal replacement 
therapy, a very expensive treatment which consumes a 
high percentage of healthcare budgets. An important 
factor to take into consideration is the small effect that 
individual-omic variants identified may have on complex 
traits, such as CKD and other kidney diseases, and con-
sequently the elevated number of patients needed to test 
to obtain benefit. It will be necessary to integrate panels 
of several biomarkers to increase the prediction of CKD 
progression. Although the cost of conventional biomark-
ers is insignificant compared to molecular biomarkers, 
the construction of disease-customised chips for routine 
use may reduce the prices considerably and make them 
cost-effective, especially if they are designed to identify 
patients with a poor prognosis.
Genomics biomarkers face additional methodological 
challenges ahead, including complexity and cost-effec-
tiveness, the establishment of adequate gold standards, 
standardisation of the different technologies and valida-
tion of the biomarkers in clinical trials, that need to be 
addressed properly before any clinical implementation 
can be incorporated into guidelines.
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